The prothrombotic activity of cancer cells in the circulation

Blood Reviews

Volumn 30, Issue 1, 2016, Pages 11-19

  Mitrugno, Annachiara ^a,b   Tormoen, Garth W ^a   Kuhn, Peter ^c   McCarty, Owen J T ^a,b  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Circulating tumor cells; Coagulation; Platelets; Thrombosis; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CELL FREE DNA; DNA; THROMBOPLASTIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 7A; FACTOR IIA; FIBRIN; FIBRINOGEN; PROTHROMBIN;

ANGIOGENESIS; ANTICOAGULANT THERAPY; CANCER GROWTH; CANCER PATIENT; CELL FUNCTION; CIRCULATING TUMOR CELL; CIRCULATION; DISEASE EXACERBATION; EXTRACELLULAR TRAP; HEMOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PRIORITY JOURNAL; PROTHROMBOTIC ACTIVITY; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; BLOOD CLOTTING; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR EMBOLISM;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; BLOOD PLATELETS; FACTOR VIIA; FIBRIN; FIBRINOGEN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PLATELET ACTIVATION; PROTHROMBIN; THROMBOPLASTIN; THROMBOSIS;

EID: 84960224716     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2015.07.001     Document Type: Article

References (117)

1. Trousseau A. Phlegmasia Alba Dolens. Lectures on clinical medicine delivered at the Hotel-Dieu 1865, 281-332.
2. Sorensen H.T., Mellemkjaer L., Olsen J.H., Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343(25):1846-1850.
3. Levitan N., Dowlati A., Remick S.C., Tahsildar H.I., Sivinski L.D., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999, 78(5):285-291.
4. Williams J.C., Mackman N. Tissue factor in health and disease. Front Biosci 2012, 4:358-372.
5. Kasthuri R.S., Glover S.L., Boles J., Mackman N. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost 2010, 36(7):764-771.
6. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009, 108(5):1447-1452.
7. Mackman N., Taubman M. Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol 2009, 29(12):1986-1988.
8. Ruf W., Mueller B.M. Tissue factor signaling. Thromb Haemost 1999, 82(2):175-182.
9. Mann K.G., Butenas S., Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003, 23(1):17-25.
10. Metcalf R.L., Fry D.J., Swindell R., McGurk A., Clamp A.R., Jayson G.C., et al. Thrombosis in ovarian cancer: a case control study. Br J Cancer 2014, 110(5):1118-1124.
11. Callander N.S., Varki N., Rao L.V. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992, 70(5):1194-1201.
12. Koizume S., Jin M.S., Miyagi E., Hirahara F., Nakamura Y., Piao J.H., et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006, 66(19):9453-9460.
13. Muller I., Klocke A., Alex M., Kotzsch M., Luther T., Morgenstern E., et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003, 17(3):476-478.
14. Furie B., Furie B.C. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004, 10(4):171-178.
15. Falati S., Liu Q., Gross P., Merrill-Skoloff G., Chou J., Vandendries E., et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003, 197(11):1585-1598.
16. Thomas G.M., Panicot-Dubois L., Lacroix R., Dignat-George F., Lombardo D., Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009, 206(9):1913-1927.
17. Yu J.L., May L., Lhotak V., Shahrzad S., Shirasawa S., Weitz J.I., et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005, 105(4):1734-1741.
18. Rong Y., Post D.E., Pieper R.O., Durden D.L., VAN Meir E.G., Brat D.J. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005, 65(4):1406-1413.
19. Boccaccio C., Sabatino G., Medico E., Girolami F., Follenzi A., Reato G., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005, 434(7031):396-400.
20. Vrana J.A., Stang M.T., Grande J.P., Getz M.J. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 1996, 56(21):5063-5070.
21. Bach R.R. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006, 26(3):456-461.
22. Ahamed J., Versteeg H.H., Kerver M., Chen V.M., Mueller B.M., Hogg P.J., et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A 2006, 103(38):13932-13937.
23. Milsom C., Yu J., May L., Meehan B., Magnus N., Al-Nedawi K., et al. The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thromb Res 2007, 120(Suppl. 2):S82-S91.
24. Marrinucci D., Bethel K., Kolatkar A., Luttgen M.S., Malchiodi M., Baehring F., et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012, 9(1):016003.
25. Phillips K.G., Lee A.M., Tormoen G.W., Rigg R.A., Kolatkar A., Luttgen M., et al. The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. Am J Physiol Cell Physiol 2015, 308(3):C229-C236.
26. King M.R., Phillips K.G., Mitrugno A., Lee T.R., DE Guillebon A.M., Chandrasekaran S., et al. A physical sciences network characterization of circulating tumor cell aggregate transport. Am J Physiol Cell Physiol 2015, 308(10):C792-C802.
27. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
28. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331(6024):1559-1564.
29. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2(8):563-572.
30. Aceto N., Bardia A., Miyamoto D.T., Donaldson M.C., Wittner B.S., Spencer J.A., et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014, 158(5):1110-1122.
31. Milsom C., Rak J. Tissue factor and cancer. Pathophysiol Haemost Thromb 2008, 36(3-4):160-176.
32. Kasthuri R.S., Taubman M.B., Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009, 27(29):4834-4838.
33. Ruf W., Yokota N., Schaffner F. Tissue factor in cancer progression and angiogenesis. Thromb Res 2010, 125(Suppl. 2):S36-S38.
34. Labelle M., Hynes R.O. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012, 2(12):1091-1099.
35. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011, 11(2):123-134.
36. Egan K., Cooke N., Kenny D. Living in shear: platelets protect cancer cells from shear induced damage. Clin Exp Metastasis 2014, 31(6):697-704.
37. Nieswandt B., Hafner M., Echtenacher B., Mannel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999, 59(6):1295-1300.
38. Palumbo J.S., Potter J.M., Kaplan L.S., Talmage K., Jackson D.G., Degen J.L. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002, 62(23):6966-6972.
39. Camerer E., Qazi A.A., Duong D.N., Cornelissen I., Advincula R., Coughlin S.R. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004, 104(2):397-401.
40. Palumbo J.S., Talmage K.E., Massari J.V., LA Jeunesse C.M., Flick M.J., Kombrinck K.W., et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005, 105(1):178-185.
41. VAN Es N., Sturk A., Middeldorp S., Nieuwland R. Effects of cancer on platelets. Semin Oncol 2014, 41(3):311-318.
42. Lipinski B., Egyud L.G. Resistance of cancer cells to immune recognition and killing. Med Hypotheses 2000, 54(3):456-460.
43. Egyud L.G., Lipinski B. Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer. Med Hypotheses 1991, 36(4):336-340.
44. Placke T., Kopp H.G., Salih H.R. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun 2011, 3(4):374-382.
45. Kopp H.G., Placke T., Salih H.R. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009, 69(19):7775-7783.
46. Gersuk G.M., Westermark B., Mohabeer A.J., Challita P.M., Pattamakom S., Pattengale P.K. Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF). III. Membrane binding studies and differential biological effect of recombinant PDGF isoforms. Scand J Immunol 1991, 33(5):521-532.
47. Palumbo J.S., Barney K.A., Blevins E.A., Shaw M.A., Mishra A., Flick M.J., et al. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 2008, 6(5):812-819.
48. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12(8):895-904.
49. Crissman J.D., Hatfield J., Schaldenbrand M., Sloane B.F., Honn K.V. Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Lab Invest 1985, 53(4):470-478.
50. McCarty O.J., Mousa S.A., Bray P.F., Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 2000, 96(5):1789-1797.
51. Dardik R., Kaufmann Y., Savion N., Rosenberg N., Shenkman B., Varon D. Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: involvement of platelet GPIIb-IIIa and tumor cell alpha(v) integrins. Int J Cancer 1997, 70(2):201-207.
52. McCarty O.J., Jadhav S., Burdick M.M., Bell W.R., Konstantopoulos K. Fluid shear regulates the kinetics and molecular mechanisms of activation-dependent platelet binding to colon carcinoma cells. Biophys J 2002, 83(2):836-848.
53. Labelle M., Begum S., Hynes R.O. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A 2014, 111(30):E3053-E3061.
54. Felding-Habermann B., Habermann R., Saldivar E., Ruggeri Z.M. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem 1996, 271(10):5892-5900.
55. Burdick M.M., Konstantopoulos K. Platelet-induced enhancement of LS174T colon carcinoma and THP-1 monocytoid cell adhesion to vascular endothelium under flow. Am J Physiol Cell Physiol 2004, 287(2):C539-C547.
56. Poggi A., Stella M., Donati M.B. The importance of blood cell-vessel wall interactions in tumour metastasis. Baillieres Clin Haematol 1993, 6(3):731-752.
57. Nash G.F., Turner L.F., Scully M.F., Kakkar A.K. Platelets and cancer. Lancet Oncol 2002, 3(7):425-430.
58. Lowe K.L., Navarro-Nunez L., Watson S.P. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res 2012, 129(Suppl. 1):S30-S37.
59. Weinberg R.A. The biology of cancer 2012, Garland Science; Taylor & Francis Group, New York.
60. Schumacher D., Strilic B., Sivaraj K.K., Wettschureck N., Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013, 24(1):130-137.
61. Mitrugno A., Williams D., Kerrigan S.W., Moran N. A novel and essential role for FcgammaRIIa in cancer cell-induced platelet activation. Blood 2014, 123(2):249-260.
62. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
63. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358(19):2039-2049.
64. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
65. Pinedo H.M., Verheul H.M., D'Amato R.J., Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet 1998, 352(9142):1775-1777.
66. Pipili-Synetos E., Papadimitriou E., Maragoudakis M.E. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998, 125(6):1252-1257.
67. Contrino J., Goralnick S., Qi J., Hair G., Rickles F.R., Kreutzer D.L. Fibrin induction of tissue factor expression in human vascular endothelial cells. Circulation 1997, 96(2):605-613.
68. Iba O., Matsubara H., Nozawa Y., Fujiyama S., Amano K., Mori Y., et al. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation 2002, 106(15):2019-2025.
69. Ho-Tin-Noe B., Goerge T., Cifuni S.M., Duerschmied D., Wagner D.D. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008, 68(16):6851-6858.
70. Kisucka J., Butterfield C.E., Duda D.G., Eichenberger S.C., Saffaripour S., Ware J., et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A 2006, 103(4):855-860.
71. Goubran H.A., Stakiw J., Radosevic M., Burnouf T. Platelets effects on tumor growth. Semin Oncol 2014, 41(3):359-369.
72. Peterson J.E., Zurakowski D., Italiano J.E., Michel L.V., Fox L., Klement G.L., et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010, 85(7):487-493.
73. Verheul H.M., Hoekman K., Luykx-de Bakker S., Eekman C.A., Folman C.C., Broxterman H.J., et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997, 3:2187-2190.
74. Gisterek I., Matkowski R., Lacko A., Sedlaczek P., Szewczyk K., Biecek P., et al. Serum vascular endothelial growth factors a, C and d in human breast tumors. Pathol Oncol Res 2010, 16(3):337-344.
75. Peterson J.E., Zurakowski D., Italiano J.E., Michel L.V., Connors S., Oenick M., et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012, 15(2):265-273.
76. Klement G.L., Yip T.T., Cassiola F., Kikuchi L., Cervi D., Podust V., et al. Platelets actively sequester angiogenesis regulators. Blood 2009, 113(12):2835-2842.
77. Kerr B.A., Miocinovic R., Smith A.K., Klein E.A., Byzova T.V. Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model. Neoplasia 2010, 12(5):388-396.
78. Kuznetsov H.S., Marsh T., Markens B.A., Castano Z., Greene-Colozzi A., Hay S.A., et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2012, 2(12):1150-1165.
79. Battinelli E.M., Markens B.A., Italiano J.E. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011, 118(5):1359-1369.
80. Bambace N.M., Holmes C.E. The platelet contribution to cancer progression. J Thromb Haemost 2011, 9(2):237-249.
81. Italiano J.E., Richardson J.L., Patel-Hett S., Battinelli E., Zaslavsky A., Short S., et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111(3):1227-1233.
82. Battinelli E.M., Markens B.A., Kulenthirarajan R.A., Machlus K.R., Flaumenhaft R., Italiano J.E. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 2014, 123(1):101-112.
83. Amirkhosravi A., Amaya M., Siddiqui F., Biggerstaff J.P., Meyer T.V., Francis J.L. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets 1999, 10(5):285-292.
84. Erdemir F., Kilciler M., Bedir S., Ozgok Y., Coban H., Erten K. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 2007, 79(2):111-116.
85. Levin J., Conley C.L. Thrombocytosis associated with malignant disease. Arch Intern Med 1964, 114:497-500.
86. Stone R.L., Nick A.M., McNeish I.A., Balkwill F., Han H.D., Bottsford-Miller J., et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012, 366(7):610-618.
87. Cooke N.M., Egan K., McFadden S., Grogan L., Breathnach O.S., O'Leary J., et al. Increased platelet reactivity in patients with late-stage metastatic cancer. Cancer Med 2013, 2(4):564-570.
88. Buller H.R., VAN Doormaal F.F., VAN Sluis G.L., Kamphuisen P.W. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007, 5(Suppl. 1):246-254.
89. Li R., Ren M., Chen N., Luo M., Deng X., Xia J., et al. Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. BMC Cancer 2014, 14:167.
90. Fuchs T.A., Brill A., Duerschmied D., Schatzberg D., Monestier M., Myers D.D., et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010, 107(36):15880-15885.
91. Demers M., Krause D.S., Schatzberg D., Martinod K., Voorhees J.R., Fuchs T.A., et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012, 109(32):13076-13081.
92. Joshita S., Nakazawa K., Sugiyama Y., Kamijo A., Matsubayashi K., Miyabayashi H., et al. Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. Intern Med 2009, 48(9):687-691.
93. Savarese T.M., Mitchell K., McQuain C., Campbell C.L., Guardiani R., Wuu J., et al. Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett 2001, 162(1):105-115.
94. Lapponi M.J., Carestia A., Landoni V.I., Rivadeneyra L., Etulain J., Negrotto S., et al. Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 2013, 345(3):430-437.
95. Swystun L.L., Mukherjee S., Liaw P.C. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 2011, 9(11):2313-2321.
96. Geddings J.E., Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014, 111(4):570-574.
97. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11(6):426-437.
98. Falanga A., Marchetti M. Anticancer treatment and thrombosis. Thromb Res 2012, 129(3):353-359.
99. DE Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004, 50(3):187-196.
100. Haddad T.C., Greeno E.W. Chemotherapy-induced thrombosis. Thromb Res 2006, 118(5):555-568.
101. Connolly G.C., Khorana A.A. Risk stratification for cancer-associated venous thromboembolism. Best Pract Res Clin Haematol 2009, 22(1):35-47.
102. Deitcher S.R., Gomes M.P. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 2004, 101(3):439-449.
103. Haas S.K., Freund M., Heigener D., Heilmann L., Kemkes-Matthes B., VON Tempelhoff G.F., et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012, 18(2):159-165.
104. Maraveyas A., Waters J., Roy R., Fyfe D., Propper D., Lofts F., et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012, 48(9):1283-1292.
105. Lyman G.H., Khorana A.A., Kuderer N.M., Lee A.Y., Arcelus J.I., Balaban E.P., et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013, 31(17):2189-2204.
106. Khorana A.A., Connolly G.C. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009, 27(29):4839-4847.
107. Perry J.R., Julian J.A., Laperriere N.J., Geerts W., Agnelli G., Rogers L.R., et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010, 8(9):1959-1965.
108. Khorana A.A., Kuderer N.M., Culakova E., Lyman G.H., Francis C.W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111(10):4902-4907.
109. Ay C., Dunkler D., Marosi C., Chiriac A.L., Vormittag R., Simanek R., et al. Prediction of venous thromboembolism in cancer patients. Blood 2010, 116(24):5377-5382.
110. Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013, 122(12):2011-2018.
111. Mego M., DE Giorgi U., Broglio K., Dawood S., Valero V., Andreopoulou E., et al. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer 2009, 101(11):1813-1816.
112. Mego M., Karaba M., Minarik G., Benca J., Sedlackova T., Tothova L., et al. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients. Breast J 2015, 21(2):155-160.
113. Milsom C., Anderson G.M., Weitz J.I., Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 2007, 5(12):2550-2552.
114. Tormoen G.W., Recht O., Gruber A., Levine R.L., McCarty O.J. Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells. Phys Biol 2013, 10(5):056010.
115. Zwicker J.I., Liebman H.A., Neuberg D., Lacroix R., Bauer K.A., Furie B.C., et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009, 15(22):6830-6840.
116. Thaler J., Ay C., Mackman N., Bertina R.M., Kaider A., Marosi C., et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012, 10(7):1363-1370.
117. Tormoen G.W., Cianchetti F.A., Bock P.E., McCarty O.J. Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Front Oncol 2012, 2:110.